C4X Discovery (C4XD) has teamed with AI firm Conformetrix to maximise shape-based chemistry insights and to create drug candidates in the area of neurodegeneration. Conformetrix uses deep-learning and quantum physics for drug discovery by simulating, filtering and searching for molecules concealed from established technologies. However, it faces challenges with AI’s over-simplification when it comes to representing molecules in medicinal chemistry. C4XD will use the precise measurements from its conformational analysis platform, GTN, to give Conformetrix the molecular descriptors needed for its in silico identification platform.
C4X Discovery (C4XD) has teamed with AI firm GTN to maximise shape-based chemistry insights and to create drug candidates in the area of neurodegeneration. GTN uses deep-learning and quantum physics for drug discovery by simulating, filtering and searching for molecules concealed from established technologies. However, it faces challenges with AI’s over-simplification when it comes to representing molecules in medicinal chemistry. C4XD will use the precise measurements from its conformational analysis platform, Conformetrix, to give GTN the molecular descriptors needed for its in silico identification platform.